NellOne Therapeutics develops regenerative medicine solutions with a focus on tissue regeneration. The firm's primary solution, NELL1 protein, aims to improve outcomes for patients in the treatment of significant tissue damage as well as issues relating to inflammation. NELL1 reduces inflammation by controlling levels of pro inflammatory factors, increases cell and tissue survival under hypoxia, promotes cell division, assists in maturation of new tissues, and facitiliates stem cell recruitment to injury sites.
